Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-specific cytotoxic T lymphocytes (M.D. Anderson)
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CMV-specific cytotoxic T lymphocytes (CTLs) is an adoptive cellular immunotherapy developed by the M.D. Anderson Cancer Center for the treatment and prevention of cytomegalovirus (CMV) infection and reactivation. The therapy utilizes recipient-derived (autologous) or donor-derived T cells that are selected or expanded ex vivo to specifically target CMV-infected cells. These CTLs recognize viral antigens, most notably the 65 kDa phosphoprotein (pp65) and immediate-early protein 1 (IE-1), presented on the surface of infected cells via major histocompatibility complex (MHC) molecules. This approach is primarily evaluated in immunocompromised patients, such as allogeneic hematopoietic stem cell transplant (HSCT) recipients, to restore viral-specific immunity and control CMV replication when conventional antiviral drugs are insufficient or toxic.
- Other names
- CMV-specific T cellsCMV-CTLsrecipient-derived CMV-specific cytotoxic T cellsautologous CMV-specific cytotoxic T cellsdonor-derived CMV-specific cytotoxic T lymphocytes
02
Targets
Cytomegalovirus immediate-early protein 1 peptide-major histocompatibility complexpp65 (Cytomegalovirus phosphoprotein 65)Fas ligand-receptor axis
Beyond the preview
Go deeper on CMV-specific cytotoxic T lymphocytes (M.D. Anderson).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-specific cytotoxic T lymphocytes (M.D. Anderson).